Download PDF
Thromb Haemost
DOI: 10.1055/a-2495-1350
Stroke, Systemic or Venous Thromboembolism

C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer

Yunlong Guan
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Zeyu Gan
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Si Li 
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Xi Cao
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Ao Zeng
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Jing Li
2   Department of Oncology, Xiang yang Central Hospital, Hubei University of Arts and Science, Xiang yang, Hubei, China
,
Wei Gong
2   Department of Oncology, Xiang yang Central Hospital, Hubei University of Arts and Science, Xiang yang, Hubei, China
,
Jun Deng
3   Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Xingjie Hao
1   Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
› Author Affiliations Funding This work is supported by National Natural Science Foundation of China (No. 32470658), Fundamental Research Funds for School of Public Health, Tongji Medical College, Huazhong University of Science and Technology (2022gwzz01), and Knowledge Innovation Special Project of Wuhan.
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background Several studies have indicated that C-reactive protein (CRP) level is associated with the risk of venous thromboembolism (VTE) in the general population. However, CRP appears to be unrelated to VTE events in patients newly diagnosed with cancer. As the survival time of cancer patients increases, the effect of CRP on the long-term risk of VTE may change. We aimed to investigate the association between CRP and VTE in cancer survivors and further assess the modification effect of genetic susceptibility.

Methods The Cox proportional hazards model was used to evaluate the association between CRP levels and VTE risk as well as to investigate the joint effect of CRP and genetic susceptibility. The Kaplan-Meier curve and restricted cubic spline were used to visualize the relationship between CRP and VTE.

Results This study included 27,806 participants with cancer diagnosis at baseline in the UK Biobank. Over a follow-up period of 344,636 person-years, a total of 1,151 VTE events were recorded. Participants were divided into four groups based on CRP level quartiles. The adjusted hazard ratios (95% CIs) of Q1, Q2, Q3, and Q4 were 1.00, 1.20 (0.99–1.44), 1.25 (1.04–1.50), and 1.51 (1.25–1.82), respectively. For those with high genetic risk of VTE, high CRP had an additional increased risk for VTE.

Conclusion CRP can be used as a predictive biomarker for VTE risk in cancer survivors, especially in those with high genetic risk. Future research can explore whether prevention and treatment strategies for VTE can be developed based on CRP for cancer survivors.

Keywords

venous thromboembolism - C-reactive protein - cancer - polygenic risk score - cohort study

Ethical Approval Statement

The UK Biobank study protocols were granted by the North West Multicenter Research Ethics Committee. The application number of the UK Biobank in our study was 88159.


Data Availability Statement

All information is available from the UK Biobank (https://www.ukbiobank.ac.uk/). Data are available on application.


Authors' Contribution

Y.L.G., J.D., and X.J.H. conceived the idea for the study, planned and carried out all the statistical analyses, and drafted the manuscript. Z.Y.G., S.L., X.C., A.Z., and J.L. advised on all statistical aspects and interpreted the data. X.J.H. and W.G. provided a critical review of the manuscript. All the authors have read the manuscript and approved the final version of the manuscript.


Supplementary Material



Publication History

Received: 22 July 2024

Accepted: 02 December 2024

Accepted Manuscript online:
03 December 2024

Article published online:
27 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016; 118 (09) 1340-1347
    CrossrefPubMedSearch in Google Scholar
  • 2 Lyman GH, Khorana AA, Falanga A. et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25 (34) 5490-5505
    CrossrefPubMedSearch in Google Scholar
  • 3 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedSearch in Google Scholar
  • 4 Raisi-Estabragh Z, Cooper J, McCracken C. et al. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart 2023; 109 (13) 1007-1015
    CrossrefPubMedSearch in Google Scholar
  • 5 Strongman H, Gadd S, Matthews A. et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 2019; 394 (10203): 1041-1054
    CrossrefPubMedSearch in Google Scholar
  • 6 Paterson DI, Wiebe N, Cheung WY. et al. Incident cardiovascular disease among adults with cancer: a population-based cohort study. JACC Cardiooncol 2022; 4 (01) 85-94
    CrossrefPubMedSearch in Google Scholar
  • 7 Miller KD, Nogueira L, Devasia T. et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72 (05) 409-436
    CrossrefPubMedSearch in Google Scholar
  • 8 Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30 (08) 1672-1678
    CrossrefPubMedSearch in Google Scholar
  • 9 Hald EM, Brækkan SK, Mathiesen EB. et al. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica 2011; 96 (08) 1189-1194
    CrossrefPubMedSearch in Google Scholar
  • 10 Kanz R, Vukovich T, Vormittag R. et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9 (01) 57-63
    CrossrefPubMedSearch in Google Scholar
  • 11 Kröger K, Weiland D, Ose C. et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17 (02) 297-303
    CrossrefPubMedSearch in Google Scholar
  • 12 Englisch C, Moik F, Nopp S, Raderer M, Pabinger I, Ay C. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv 2022; 6 (24) 6274-6281
    CrossrefPubMedSearch in Google Scholar
  • 13 Thibord F, Klarin D, Brody JA. et al; Global Biobank Meta-Analysis Initiative; Estonian Biobank Research Team; 23andMe Research Team; Biobank Japan; CHARGE Hemostasis Working Group. Cross-ancestry investigation of venous thromboembolism genomic predictors. Circulation 2022; 146 (16) 1225-1242
    CrossrefPubMedSearch in Google Scholar
  • 14 Klarin D, Busenkell E, Judy R. et al; INVENT Consortium, Veterans Affairs' Million Veteran Program. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019; 51 (11) 1574-1579
    CrossrefPubMedSearch in Google Scholar
  • 15 Ghouse J, Tragante V, Ahlberg G. et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet 2023; 55 (03) 399-409
    CrossrefPubMedSearch in Google Scholar
  • 16 Guman NAM, Mulder FI, Ferwerda B. et al. Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study. J Thromb Haemost 2023; 21 (11) 3175-3183
    CrossrefPubMedSearch in Google Scholar
  • 17 Sudlow C, Gallacher J, Allen N. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12 (03) e1001779
    CrossrefPubMedSearch in Google Scholar
  • 18 Elliott P, Peakman TC, Biobank UK. UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol 2008; 37 (02) 234-244
    CrossrefPubMedSearch in Google Scholar
  • 19 Thompson DJ, Wells D, Selzam S. et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. 2022; ;2022.06.16.22276246. medRxiv
    CrossrefPubMedSearch in Google Scholar
  • 20 Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 2018; 3 (07) e323-e332
    CrossrefPubMedSearch in Google Scholar
  • 21 Panova-Noeva M, Schulz A, Arnold N. et al. Coagulation and inflammation in long-term cancer survivors: results from the adult population. J Thromb Haemost 2018; 16 (04) 699-708
    CrossrefPubMedSearch in Google Scholar
  • 22 Gade IL, Brækkan SK, Næss IA. et al. Long-term incidence of venous thromboembolism in cancer: the Scandinavian thrombosis and cancer cohort. TH Open 2018; 2 (02) e131-e138
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedSearch in Google Scholar
  • 24 Kahn SR, Ducruet T, Lamping DL. et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005; 165 (10) 1173-1178
    CrossrefPubMedSearch in Google Scholar
  • 25 Yuan S, Sun Y, Chen J. et al. Long-term risk of venous thromboembolism among patients with gastrointestinal non-neoplastic and neoplastic diseases: a prospective cohort study of 484 211 individuals. Am J Hematol 2024; 99 (02) 172-181
    CrossrefPubMedSearch in Google Scholar
  • 26 Yuan YE, Haas AV, Williams GH, Taylor H, Seely EW, Adler GK. Association between Life's Simple 7 and biomarkers of cardiovascular disease: aldosterone, interleukin-6, C-reactive protein. J Am Heart Assoc 2023; 12 (10) e028718
    CrossrefPubMedSearch in Google Scholar
  • 27 Evans CR, Hong CP, Folsom AR. et al. Lifestyle moderates genetic risk of venous thromboembolism: the ARIC study. Arterioscler Thromb Vasc Biol 2020; 40 (11) 2756-2763
    CrossrefPubMedSearch in Google Scholar
  • 28 Gupta NK, de Lemos JA, Ayers CR, Abdullah SM, McGuire DK, Khera A. The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. J Am Coll Cardiol 2012; 60 (13) 1148-1155
    CrossrefPubMedSearch in Google Scholar